Umbilical cord blood transplantation for myeloid malignancies
Umbilical cord blood transplantation for myeloid malignancies
复制标题
DOI：
10.1097/moh.0b013e32802f7da4
复制
发表时间：
2007-03-01
影响因子：
3.2
通讯作者：
Wagner, John E.
中科院分区：
文献类型：
--
作者：
Brunstein, Claudio G.;Baker, K. Scott;Wagner, John E.
Purpose of reviewTo review the available data on the outcomes of pediatric and adult patients with acute myeloid leukemia, myelodysplastic syndrome and chronic myelogenous leukemia after umbilical cord blood transplantation.Recent findingsThe literature shows that after umbilical cord blood transplantation the relapse rate, disease-free survival and overall survival of patients with myeloid malignancies is similar to other hematopoietic stem cells sources. Disease status at the time of transplantation is found in several studies to be a very important determinant of long-term outcome. Newer strategies such as double umbilical cord blood transplant and utilization of nonmyeloblative conditioning regimens show promising results.SummaryUmbilical cord blood is a valuable alternative source of hematopoietic stem cells for transplantation of patients with myeloid malignancies who need an allogeneic transplant, but lack a suitable sibling donor.
